In their search for such improved antiandrogens, Tran et al. (2009) screened nearly 200 thiohydantoin derivatives of RU59063 – a non-steroidal AR agonist with a relatively high affinity and selectivity over other nuclear hormone receptors – for retained activity in human PCa cells that overexpressed the AR protein, which is also clinically observed in the castration-resistant disease setting. This evidence concerns the gene AR and posterior cortical atrophy.